Mirum Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Mirum Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Mirum Pharmaceuticals Inc
Rating: 1.680486125
Author: Trendlyne DVM scores

Momentum Trap

about

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestat...

102.18 -9.21 (-8.27%)

New 52W High in past week

1.7M

XNAS Volume

XNAS 15 May, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Mirum Pharma Inc is on 20 May 2026 for the purpose of RBC - 2026 Global Healthcare Conference See details

Low Financial Strength

27.8 / 100

Expensive Valuation

8.3 / 100

Technically Bullish

70.6 / 100

Momentum Trap These stocks have weak financials and expensive valuation. Buying interest may quickly dissipate. Investors should exercise caution View Similar Embed DVM

147

1Yr Price target upside is 44%

11 analysts

Mirum Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Mirum Pharma Inc Live Stock Price Today, Share Analysis and Chart

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestat...

New 52W High in past week

SWOT Analysis

Mirum Pharma Inc Live Price Chart